Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection.

Autor: Smith M; Department of Obstetrics and Gynecology, NYU Langone Health, New York, NY, United States of America., Lara OD; Department of Obstetrics and Gynecology, NYU Langone Health, New York, NY, United States of America., O'Cearbhaill R; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Weill Cornell Medical College, New York, NY, United States of America., Knisely A; Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, NY, United States of America., McEachron J; Department of Obstetrics and Gynecology, State University of New York Downstate Medical Center, Brooklyn, NY, United States of America., Gabor L; Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, United States of America., Carr C; Department of Obstetrics, Gynecologic and Reproductive Science, Division of Gynecologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America., Blank S; Department of Obstetrics, Gynecologic and Reproductive Science, Division of Gynecologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America., Prasad-Hayes M; Department of Obstetrics, Gynecologic and Reproductive Science, Division of Gynecologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America., Frey M; Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, United States of America., Jee J; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America., Fehniger J; Department of Obstetrics and Gynecology, NYU Langone Health, New York, NY, United States of America., Wang Y; Department of Population Health, NYU Langone Health, New York, NY, United States of America., Lee YC; Department of Obstetrics and Gynecology, State University of New York Downstate Medical Center, Brooklyn, NY, United States of America., Isani S; Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, United States of America., Wright JD; Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, NY, United States of America., Pothuri B; Department of Obstetrics and Gynecology, NYU Langone Health, New York, NY, United States of America. Electronic address: bhavana.pothuri@nyulangone.org.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2020 Dec; Vol. 159 (3), pp. 618-622. Date of Electronic Publication: 2020 Sep 25.
DOI: 10.1016/j.ygyno.2020.09.036
Abstrakt: Objective: Elevated inflammatory markers are predictive of COVID-19 infection severity and mortality. It is unclear if these markers are associated with severe infection in patients with cancer due to underlying tumor related inflammation. We sought to further understand the inflammatory response related to COVID-19 infection in patients with gynecologic cancer.
Methods: Patients with a history of gynecologic cancer hospitalized for COVID-19 infection with available laboratory data were identified. Admission laboratory values and clinical outcomes were abstracted from electronic medical records. Severe infection was defined as infection requiring ICU admission, mechanical ventilation, or resulting in death.
Results: 86 patients with gynecologic cancer were hospitalized with COVID-19 infection with a median age of 68.5 years (interquartile range (IQR), 59.0-74.8). Of the 86 patients, 29 (33.7%) patients required ICU admission and 25 (29.1%) patients died of COVID-19 complications. Fifty (58.1%) patients had active cancer and 36 (41.9%) were in remission. Patients with severe infection had significantly higher ferritin (median 1163.0 vs 624.0 ng/mL, p < 0.01), procalcitonin (median 0.8 vs 0.2 ng/mL, p < 0.01), and C-reactive protein (median 142.0 vs 62.3 mg/L, p = 0.02) levels compared to those with moderate infection. White blood cell count, lactate, and creatinine were also associated with severe infection. D-dimer levels were not significantly associated with severe infection (p = 0.20).
Conclusions: The inflammatory markers ferritin, procalcitonin, and CRP were associated with COVID-19 severity in gynecologic cancer patients and may be used as prognostic markers at the time of admission.
Competing Interests: Declaration of Competing Interest Maria Smith, Olivia D. Lara, Anne Knisely, Jennifer McEachron, Lisa Gabor, Caitlin Carr, Stephanie Blank, Monica Prasad-Hayes, Melissa Frey, Julia Fehniger, Yi-chun Lee, Sara Isani, and Yuyan Wang have nothing to disclose. Roisin O'Cearbhaill reports personal fees from Tesaro, personal fees from Glaxosmithkline, personal fees from Regeneron, other from Genentech USA, outside the submitted work; and Non-compensated steering committee member for the PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies. Justin Jee reports a patent 16/686,663, 2020 licensed to MDSeq Inc. Jason D. Wright receives research funding from Merck and is a consultant for Clovis Oncology. Bhavana Pothuri reports grants, personal fees and non-financial support outside the submitted work; institutional PI for industry sponsored trials from Tesaro/GSK, AstraZeneca, Merck, Genentech/ Roche, and Clovis Oncology. Compensated advisory boards include Tesaro/GSK, AstraZeneca, Merck, Mersana and Eisai.
(Copyright © 2020. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: